|
|||||
|
|
Genomic analyses of high‐grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities |
|
| Authors: | Haider Mahdi,Amy Joehlin‐ Price,Esther Elishaev,Afshin Dowlati,Ata Abbas |
| Abstract: | |
| Keywords: | CDK4/6 inhibitors gynecologic neuroendocrine carcinoma immunotherapy targets PARP inhibitors RB1 YAP1 |